Guideline for tumor presentation with (F-18) fluorodeoxyglucose (FDG);Leitlinie zur tumordarstellung mit (F-18)-fluordeoxyglukose (FDG)

NuklearMedizin

Volumn 38, Issue 6 A, 1999, Pages 267-269

  Knapp, W H ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

DIAGNOSTIC IMAGING; HUMAN; IMAGING SYSTEM; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; REVIEW; TUMOR LOCALIZATION; TUMOR SCINTISCANNING;

FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASMS; PRACTICE GUIDELINES; QUALITY ASSURANCE, HEALTH CARE; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0032823509     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (14)

1. Choi Y, Brunken RC, Hawkins RA, et al. Factors affecting myocardial 2-[F-18]fluoro-2-deoxy-D-glucose uptake in positron emission tomography studies of normal humans. Eur J Nucl Med 1993; 20: 308-18.
2. Conti PS. Introduction to imaging brain tumor metabolism with positron emission tomography (PET). Cancer Invest 1995; 13: 244-59.
3. Di Chiro G. Positron emission tomography using [18F]fluorodexy-glucose in brain tumors - a powerful diagnostic und prognostic tool. Invest Radiol 1987; 22: 360-71.
4. Duhaylongsod FG, Lowe VJ, Patz EF Jr, et al. Detection of primary one recurrent lung cancer by means of F-18-fluorodeoxyglucose positron emission tomography (FDG PET). J Thor Cardiovasc Surg 1995; 110: 130-9.
5. Engel H, Steinert H, Buck A, et al. Whole-body PET: physiologic and artifactual fluoro-deoxyglucose accumulations. J Nucl Med 1996; 37: 441-6.
6. Griffeth LK, Dehdashti F, McGuire AH, et al. PET evaluation of soft-tissue masses with fluorine-18-fluoro-2-deoxy-D-glucose. Radiology 1992; 182: 185-94.
7. Hoh CK, Hawkins RA, Glaspy JA, et al. Cancer detection with whole-body PET using 2-[18F] fluoro-2-deoxy-D-glucose. J Comput Assist Tomogr 1993; 17: 582-9.
8. Lindholm P, Minn H, Leskinen-Kallio S, et al. Influence of the blood glucose concentration on FDG uptake in cancer - a PET study. J Nucl Med 1993; 34: 1-6.
9. Mogard J, Kihlstrom L, Ericson K, et al. Recurrent tumor vs. radiation effects after gamma knife rodiosurgery of intracerebral metastases: diagnosis with PET-FDG. J Comput Assist Tomogr 1994; 18: 177-81.
10. Newman JS, Francis IR, Kaminski MS, et al. Imaging of lyrophoma with PET with 2-[F18]-fluoro-2-deoxy-D-glucose: correlation with CT. Radiology 1994; 190: 111-6.
11. Nieweg OE, Kim EE, Wong WH, et al. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer. Cancer 1993; 71: 3920-5.
12. Patz EF Jr, Love VJ, Hoffmann JM, et al. Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-[F-18]-2-deoxy-D-glucose. Radiology 1994; 191: 379-82.
13. Reske S, Bares R, Büll U, et al: Klinische Wertigkeit der Positronen-Emissions-Tomographie (PET) bei onkologischen Fragestellungen: Ergebnisse einer interdisziplinären Konsensuskonferenz. Nuklearmedizin 1996; 35: 42-52.
14. Wahl RL, Zasadny K, Helvie M, et al. Metabolic monitoring of breast cancer chemohormonotheraphy using positron emission tomography: initial evaluation. J Clin Oncol 1993; 11: 2101-11.